Preserved Liver Transplant After PD-1 Pathway Inhibitor for Hepatocellular Carcinoma

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Gastroenterology

• Publication date

  2017-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ajg.2017.387PMID 29215617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant

  2017cited by this paper
• Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

  2017cited by this paper
• Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab.

  2017cited by this paper
• Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features

  2016cited by this paper
• PD-L 1 expression in hepatocellular carcinoma : relationship with clinical and pathological features

  2016cited by this paper
• Tumor Regression and Allograft Rejection after Administration of Anti-PD-1.

  2016cited by this paper
• Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation

  2015cited by this paper

• Immune Checkpoint Inhibitor-induced Hepatitis, an Emerging Issue in Precision Cancer Therapy Era: A Narrative Literature Review

  2026cites this paper
• Post-Transplant Hepatocellular Carcinoma: Balancing Immunosuppression and Immune Checkpoint Inhibitors.

  2026cites this paper
• Predicting and Managing Hepatocellular Carcinoma Recurrence After Liver Transplant: A Single-Center Experience 2012–2024

  2026cites this paper
• Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors

  2025cites this paper
• Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review

  2025cites this paper
• Current knowledge about immunotherapy response after liver transplantation of patients with liver cancer.

  2025cites this paper
• Hepatocellular carcinoma and liver transplant: What about neo- and adjuvant immunotherapy.

  2025cites this paper
• Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?

  2024cites this paper
• Suppressing, stimulating and/or inhibiting: the evolving management of HCC patient after liver transplantation.

  2024cites this paper
• Immune checkpoint inhibitors in the post-transplant landscape of hepatocellular carcinoma: A systematic literature review.

  2024cites this paper
• APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024

  2024cites this paper
• Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies.

  2024cites this paper
• Immunotherapy in Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review

  2024cites this paper
• Immunotherapy and Liver Transplantation: The Future or the Failure?

  2023cites this paper
• Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma

  2023cites this paper
• Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review

  2023cites this paper
• When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road.

  2023cites this paper
• Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.

  2023cites this paper
• Transplant Oncology: An Emerging Discipline of Cancer Treatment

  2023cites this paper
• Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology

  2023cites this paper
• Immunotherapy for transplantation of hepatocellular carcinoma: the next frontier in adjunctive therapy

  2023cites this paper
• Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?

  2023cites this paper
• Immunotherapy for hepatocellular carcinoma in liver transplant patients (Literature review)

  2023cites this paper
• Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data

  2023cites this paper
• Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.

  2022cites this paper
• Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis

  2022cites this paper
• Immune checkpoint blockade for organ-transplant recipients with cancer: A review.

  2022cites this paper
• Immune microenvironment and therapeutic progress of recurrent hepatocellular carcinoma after liver transplantation

  2022cites this paper
• Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons

  2022cites this paper
• Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant

  2022cites this paper
• A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen

  2022cites this paper
• Immune Checkpoint Inhibitor Therapy Before Liver Transplantation—Case and Literature Review

  2022cites this paper
• Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View

  2022cites this paper
• Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.

  2022cites this paper
• An analysis report on the application of immune checkpoint inhibitors after liver transplantation

  2022cites this paper
• Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates

  2022cites this paper
• Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review

  2022cites this paper
• Biological therapies in patients with liver disease: are they really lifesavers?

  2021cites this paper
• Risk factors and management of post-liver transplant recurrence of hepatocellular carcinoma

  2021cites this paper
• Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review

  2021cites this paper
• The management of post-transplantation recurrence of hepatocellular carcinoma

  2021cites this paper
• Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung

  2021cites this paper
• Immunotherapy after liver transplantation: Where are we now?

  2021cites this paper
• Role of Intrahepatic Regional Immunity in Post-Transplant Cancer Recurrence

  2021cites this paper
• Immunotherapy in older patients with hepatocellular carcinoma.

  2021cites this paper
• Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung The use of immuno-oncologic therapy in hepatocellular carcinoma in the context of liver transplantation. An interdisciplinary benefit/risk asse

  2021cites this paper
• Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.

  2020cites this paper
• The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 patients.

  2020cites this paper
• Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.

  2020cites this paper
• Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: one case report and literature review.

  2020cites this paper
• Immune Checkpoint Inhibitors in Transplantation-A Case Series and Comprehensive Review of Current Knowledge.

  2020cites this paper
• Ipilumumab for hepatocellular cancer in a liver transplant recipient, with durable response, tolerance and without allograft rejection.

  2020cites this paper
• The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.

  2020cites this paper
• Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.

  2020cites this paper
• Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?

  2019cites this paper
• Liver graft rejection following immune checkpoint inhibitors treatment: a review

  2019cites this paper
• PD-1 Blockade in a Liver Transplant Recipient With Microsatellite Unstable Metastatic Colorectal Cancer and Hepatic Impairment.

  2019cites this paper
• Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation.

  2019cites this paper
• Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients

  2018cites this paper
• Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients

  2018cites this paper
• Pembrolizumab Monotherapy in Relapsed Hepatocellular Carcinoma Post Living Donor Liver Transplantation and Sorafenib

  2018cites this paper
• Knowns and Unknowns: the Safety and Efficacy of Cancer Immunotherapy in Chronic Liver Disease

  2018cites this paper
• Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.

  2018influential citation
• Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm

  2018cites this paper
• Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

  2018cites this paper
• Use of checkpoint inhibitors in liver transplant recipients

  2018cites this paper
• World Journal of Gastrointestinal Surgery

  year unknowncites this paper